Asset Details
Do you wish to reserve the book?
Pharmacokinetics of apixaban in patients undergoing pancreaticoduodenectomy (PAP-UP)
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Pharmacokinetics of apixaban in patients undergoing pancreaticoduodenectomy (PAP-UP)
Do you wish to request the book?
Pharmacokinetics of apixaban in patients undergoing pancreaticoduodenectomy (PAP-UP)
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Pharmacokinetics of apixaban in patients undergoing pancreaticoduodenectomy (PAP-UP)
2024
Overview
The impact of pancreaticoduodenectomy on absorption of drugs in the duodenum remains largely unknown. We aim to characterize the pharmacokinetics of apixaban in patients who had previously undergone pancreaticoduodenectomy.
A single 10-mg dose of apixaban was administered to 4 volunteers who underwent pancreaticoduodenectomy at least 6 months prior. The maximum plasma apixaban concentration (C
) and area under the plasma concentration time-curve (AUC
, AUC
) were compared against healthy historical control subjects (N = 12). Geometric mean ratios (GMR) with 90% confidence interval (CI) were calculated for determination of comparative bioequivalence.
In pancreaticoduodenectomy patients, AUC
and AUC
were 1,861 and 2,080 ng×h/mL, respectively. The GMRs of AUC
and AUC
between study subjects and healthy controls were 1.27 (90% CI 0.88 - 1.83) and 1.18 (90% CI 0.82 - 1.72). The mean C
of apixaban was 201 ng/mL (SD 15.6) occurring at a median t
of 3.25 hours (range 2.5 - 4 hours). The GMR of C
between study subjects and healthy controls was 1.12 (90% CI 0.77 - 1.63).
The pharmacokinetic characteristics of apixaban in subjects who had undergone pancreaticoduodenectomy are not significantly different from those of healthy controls. Though the sample size of this study is small, results suggest that no change to apixaban dose regimen is needed in patients who have had a pancreaticoduodenectomy.
Publisher
Dustri - Verlag Dr. Karl Feistle GmbH & Co. KG,Dustri-Verlag Dr. Karl Feistle
Subject
/ Aged
/ Factor Xa Inhibitors - administration & dosage
/ Factor Xa Inhibitors - pharmacokinetics
/ Female
/ Humans
/ Male
/ Pancreaticoduodenectomy - adverse effects
/ Pyrazoles - administration & dosage
/ Pyrazoles - pharmacokinetics
/ Pyridones - administration & dosage
